This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Bovie Medical Corporation Announces Leonard Keen As General Counsel

Bovie Medical Corporation (the “Company”) (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, today announced that it has employed Mr. Leonard Keen, Esq. as Vice President and General Counsel, effective March 2, 2010. Mr. Keen is responsible for managing the Company’s legal and strategic affairs, and working as a member of the executive management team to strengthen operations for growth and competitiveness.

“We are pleased that Mr. Keen has joined Bovie at this time. He is multi-skilled and will be involved in areas of the Company’s business development requiring his legal and technical advice,” stated Andrew Makrides, President and Chief Executive Officer of Bovie Medical.

Prior to joining the Company, Mr. Keen has worked as an attorney, business executive, entrepreneur and technologist. He served as a partner with Kaplan, Ward & Patel, an associate with Allen Dyer Doppelt Milbrath & Gilchrist and a solo practitioner where he specialized in intellectual property and business law. He also served as Vice President of Legal and Strategic Affairs at Kinetics, Inc. (a NCR Subsidiary) and as Chief Information Officer at Payroll Transfers, Inc.

Mr. Keen received a Bachelor of Science degree in Chemistry/Mathematics from the University of Miami and a Juris Doctor, with honors, from the University of Florida Levin College of Law. In addition to being a U.S. registered patent attorney and member of the Florida Bar, Mr. Keen has extensive experience in the technical, business and executive management fields.

An employment agreement with Mr. Keen was entered into on March 2, 2010, and as part thereof, he was awarded a restricted non-qualified stock option for an aggregate of 100,000 shares of common stock, exercisable at the closing price on that date. The option has a ten year term and vests over seven years, or at the rate of 14.29 percent per annum. This press release is issued in accordance with the exemption afforded under Section 711(a) of the NYSE AMEX Company Guide which exempts certain stock option grants made as an inducement to employment from the stockholder approval requirement.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
BVX $3.38 0.00%
AAPL $128.46 0.00%
FB $78.97 0.00%
GOOG $558.40 0.00%
TSLA $203.34 0.00%

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs